FujiFilm

24M Technologies, founded in 2010 and based in Cambridge, Massachusetts, specializes in the development of energy storage systems tailored for grid and transportation applications. The company manufactures lithium-ion batteries that enhance the operational reliability, economics, and efficiency of electric power systems. Its innovative design features binder-free semisolid electrodes and unit cells, which streamline the battery recycling process by eliminating the need for complex hydro or pyrometallurgical methods. This approach facilitates the direct reuse of active materials, ultimately enabling clients to improve efficiency and reduce costs associated with end-of-life battery management.

Cuorips Inc. is a Japanese company focused on the research, development, and commercialization of induced pluripotent stem (iPS) cell-derived cardiomyocyte sheets and cell therapeutic products. Founded in 2017, Cuorips, formerly known as Cuore Inc., operates from its headquarters in Chuo, Japan, with an additional office in Osaka. The company aims to advance medical care by leveraging cutting-edge technology to create innovative solutions in the field of regenerative medicine.

Rege Nephro Co., Ltd. engages in the research and development, production, and marketing of renal disease therapeutics using nephron progenitor cells. It also produces kidney organoids capable of nephrotoxicity screening for drug discovery in applied research. The company was founded in 2019 and is based in Kyoto, Japan.

Nanox Vision is a healthcare technology company that specializes in advanced medical imaging solutions. Incorporated in 2011 and based in Gibraltar, the company has developed the Nanox System, which provides Medical Screening as a Service (MSaaS) aimed at preventative healthcare. This system is built on proprietary cold cathode technology, originally derived from innovations in high-definition flat panel displays. After over two decades of research and development and substantial financial investment, Nanox has created a unique imaging platform that enhances X-ray capabilities. Central to this technology is a nano-scale chip developed using specialized nanofabrication techniques, which allows for increased power density and uniformity in imaging. The Nanox System is designed to support diverse applications in medical imaging and is complemented by additional peripheral technologies to maximize its real-world utility.

Fuji Xerox New Zealand forms part of a global enterprise group delivering market leading business and document management services. Our experienced, local team are committed to providing innovative solutions helping New Zealand businesses maximise efficiency and drive down costs. With a comprehensive technologies, solutions and services suite extending from digital printing to document management to business process outsourcing, we make it easier for our customers to reduce printing costs, streamline processes and automate tasks. At the heart of Fuji Xerox New Zealand is a passion to be strong, kind and interesting. We value long term relationships with our people and communities and have a strong track record of actively supporting environmental, educational and sporting initiatives. By providing scalable, cost effective printing and document management solutions Fuji Xerox New Zealand helps New Zealand businesses to grow and transform.

Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.

PuREC is a developer of a culture technology intended to bring efficacy to the treatment process.The company leverages technology to develop rapidly changing cell therapies and mesenchymal stem cells therapies, enabling clients to fight a variety of diseases and change the future of transplantation medicine.

JUNTEN BIO is a company is to develop new technologies in the field of regenerative medicine.

LPixel Inc. is a Tokyo-based company that specializes in life science image analysis software solutions. Founded in 2014 as a spin-out from the University of Tokyo, LPixel offers a range of products including ImageJ plugins for life science researchers, LP-exam for detecting image manipulation and plagiarism, and IMACEL, a cloud-based image analysis system powered by artificial intelligence. The company is also dedicated to developing software solutions aimed at improving cancer diagnoses. In addition to its software offerings, LPixel provides educational programs for life science researchers and students, thereby enhancing research efficiency and innovation in the field.

Suono Bio, Inc. is focused on developing a novel platform technology for the rapid and localized delivery of therapeutic products, specifically targeting the gastrointestinal (GI) tract. Incorporated in 2016 and based in Medford, Massachusetts, the company aims to facilitate the administration of small molecules, proteins, vaccines, and nucleic acids without the need for encapsulation. Preclinical studies have shown the platform's effectiveness in delivering various therapeutics both locally and systemically, which supports its potential for treating inflammatory-mediated diseases. This innovative approach may offer significant advancements in therapeutic delivery, enhancing patient recovery from gastrointestinal conditions.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

IS Japan, founded in 1989, manufactures in vitro fertilization products, products for cell culture, and products for research on regenerative medicine and cell therapy, and distributes Irvine Scientific's products in and outside Japan.

FUJIFILM Irvine Scientific, Inc., is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivaled service and quality to scientists working in biopharmaceuticals, cell therapy, and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA, and Tokyo, Japan. The company’s consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years, FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

Xerox Holdings Corporation is a global leader in document management technology and services, operating in the United States, Europe, Canada, and beyond. The company designs, develops, and sells a range of solutions, including intelligent workplace services and digital services that enhance workflow automation, content management, and communication. Xerox offers various printing solutions, such as monochrome, color, and multifunction printers, along with digital presses and IT services including network infrastructure and cloud support. The company's software portfolio features FreeFlow for print job automation, XMPie for personalization in communications, and DocuShare for content management. Additionally, Xerox India Limited, a subsidiary, provides document management solutions tailored to government, education, and commercial sectors, focusing on enhancing the efficiency of document creation and sharing. Founded in 1906 and headquartered in Norwalk, Connecticut, Xerox is committed to improving operational performance for businesses and government entities through innovative technology and services.

EdiGENE Inc. is a biotechnology company that specializes in developing therapeutics for genetic disorders. Founded in 2016 and headquartered in Tokyo, Japan, with additional offices in Cambridge, Massachusetts, the company leverages its proprietary technologies, including clustered regularly interspaced short palindromic repeats (CRISPR) and guide nucleotide directed modulation (GNDM), to create innovative treatments. EdiGENE's focus is on addressing unmet medical needs through its advanced therapeutic solutions, supported by a strong foundation of intellectual property licensed from the University of Tokyo.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Cyfuse Biomedical develops tissue fabrication systems and cell-based products in Japan and internationally. The company offers 3D BioFabrication systems and related consumables; develops and licenses 3D tissue products for therapeutic and drug development use; and engages in contract manufacturing of 3D tissue products for research purposes. Its products applications include blood vessel grafts for blood access of hemodialysis patients or coronary artery bypass grafts; cardiac grafts for drug toxicology screening or supplemental therapy of myocardial infarction; cartilage grafts for plastic surgery or reconstruction; and hepatocyte grafts for drug metabolism screening or in-vivo production of clotting factors in the treatment of hemophilia. Cyfuse Biomedical was founded in 2010 and is based in Tokyo, Japan.

Tokiwa Bio Inc. is a company based in Tsukuba, Japan, that specializes in the manufacture and sale of drugs associated with regenerative medicine and gene therapy. Founded in 2014, the company develops biopharmaceuticals, antibody drugs, and research reagents. Tokiwa Bio focuses on advancing therapeutic solutions that harness the potential of regenerative medicine, aiming to contribute to healthcare innovation and improvement.

BONAC Corporation focuses on the research, development, manufacturing, and commercialization of nucleic acid pharmaceutical products, utilizing advanced nucleic acid platform technology. Established in 2010 and headquartered in Kurume, Japan, with an office in Tokyo, the company specializes in the production and sale of nucleic acid ingredients. BONAC offers a comprehensive suite of services that includes drug substance manufacturing and support for drug development, aiming to facilitate access to innovative drug substances for pharmaceutical and cosmetic manufacturers. Through its efforts, BONAC addresses unmet medical needs by advancing RNA technology and developing effective nucleic acid medicines.

BONAC Corporation focuses on the research, development, manufacturing, and commercialization of nucleic acid pharmaceutical products, utilizing advanced nucleic acid platform technology. Established in 2010 and headquartered in Kurume, Japan, with an office in Tokyo, the company specializes in the production and sale of nucleic acid ingredients. BONAC offers a comprehensive suite of services that includes drug substance manufacturing and support for drug development, aiming to facilitate access to innovative drug substances for pharmaceutical and cosmetic manufacturers. Through its efforts, BONAC addresses unmet medical needs by advancing RNA technology and developing effective nucleic acid medicines.

RegCell is focused on developing innovative therapies for autoimmune diseases and cancer by enhancing or regulating the immune system. The company specializes in creating cell therapies that aim to address significant unmet medical needs. By returning regulatory T cells to the patient and activating them in vitro, RegCell seeks to provide effective treatment options for individuals suffering from these challenging conditions. Through its novel approach, the company aims to improve patient outcomes and address the complexities associated with autoimmune disorders and cancer.

Cynata Therapeutics Limited is an Australian company focused on developing and commercializing its proprietary Cymerus™ mesenchymal stem cell technology for therapeutic applications. The company’s lead product candidate, CYP-001, has completed Phase I clinical trials aimed at treating graft versus host disease. In addition to this, Cynata is exploring treatments for various conditions such as asthma, heart attack, diabetic wounds, coronary artery disease, and acute respiratory distress syndrome, among others, which are currently in preclinical stages. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) derived from adult donors, enabling the efficient and scalable production of mesenchymal stem cells. This innovative approach addresses existing limitations in stem cell manufacturing, allowing for virtually limitless quantities of therapeutic cells without the need for continuous donor sourcing. Cynata collaborates with several prestigious institutions, including Monash University and Massachusetts General Hospital, to advance its research and development efforts. Founded in 2011 and based in Carlton, Australia, Cynata is positioned to significantly contribute to the field of regenerative medicine.

Ultra Pure Solutions, Inc. is one of the largest manufacturers of high purity chemicals in North America.

FUJIFILM TeraMedica, Inc. is a healthcare informatics company based in Milwaukee, Wisconsin, specializing in unrestricted medical image management solutions. Founded in 2001, the company has developed a patient-centric vendor neutral archive system designed to meet the diverse needs of healthcare enterprises. Its key offerings include Synapse VNA, a clinical content data management system suitable for various medical specialties; Synapse Mobility Enterprise Viewer, a lightweight browser-based viewer; Synapse VNA Remote, which connects remote institutions; and Synapse VNA Connext, a point-of-data capture tool for iPads. TeraMedica's software has been deployed at over 600 locations across six continents. The company also provides technical support, training, and professional services to its clients, which include healthcare facilities in the United States and internationally. In May 2015, TeraMedica became a subsidiary of Fujifilm Medical Systems USA, Inc.

Cellular Dynamics International Inc., (CDI) is a developer and manufacturer of fully functioning cells in industrial quantities to precise specifications. CDI's proprietary products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our products, among other purposes, for drug discovery and screening, to test the safety and efficacy of their small molecule and biological drug candidates, for stem cell banking, and in the research and development of cellular therapeutics.

SonoSite, Inc. specializes in hand-carried ultrasound technology and is a leader in the global portable ultrasound market. The company excels in ASIC design, enabling it to deliver imaging performance comparable to traditional, larger ultrasound machines in a compact, laptop-sized system. This innovation is reshaping the diagnostic ultrasound market by enhancing efficiency in existing clinical applications and introducing new point-of-care uses where traditional ultrasound systems were previously impractical due to size or cost. Since its inception in 1999, SonoSite has sold over 40,000 systems, earning a reputation for exceptional performance, user-friendliness, and durability in its products.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Dimatix is a world leader in the research, development, manufacture and sale of printheads used in industrial inkjet printers, which are increasingly being used in such fields as outdoor advertising and packaging materials. As such, the company supplies printheads and provides after-sales service to printer manufacturers and various other users. Using MEMS1, Dimatix has developed advanced piezoelectric printheads2 that feature superior quality and excellent durability.

Perseus Proteomics Inc. is a biotechnology company based in Tokyo, Japan, focused on drug discovery and advanced antibody technology. Founded in 2001, the company specializes in antibody discovery, engineering, and target discovery, along with functional protein expression. Its services include mouse hybridoma sequencing, recombinant protein production, and contract research support for antibody development. Perseus Proteomics is dedicated to creating innovative antibody products and new medicines to improve healthcare outcomes for patients globally.

Sericol is a global corporation engaged in the development, manufacturing and sale of inks for screen and package printing as well as industrial inkjet inks and materials. With inks for screen printing and wide format digital UV inkjet inks, the company maintains a leading market share position worldwide.